141 filings
Page 2 of 8
8-K
j83iv8kynmx0emg5w6
18 Jul 23
Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
7:47am
8-K
5nk6057cghpo89rbfa7
13 Jun 23
Departure of Directors or Certain Officers
7:04am
8-K
cee3r25h6z9ficr8ld
8 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
vf6kjp
7 Jun 23
Regulation FD Disclosure
7:31am
8-K
v1l 7r5813f
2 Jun 23
Other Events
8:01am
8-K
oea61dze0a0usnno5dud
31 May 23
Regulation FD Disclosure
8:00am
8-K
ujqn8yz l03
30 May 23
Regulation FD Disclosure
7:34am
8-K
w2soh87
25 May 23
Entry into a Material Definitive Agreement
8:05am
8-K
f46zm2re7g2iz2e6
23 May 23
Other Events
7:59am
8-K
gyu uvr820f
9 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
ce8pycq90m0s
8 May 23
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
7:41am
8-K
rrnr9 5b16gx1xmrun
8 May 23
Submission of Matters to a Vote of Security Holders
7:40am
8-K
9875w 8q17f
28 Apr 23
Amendments to Articles of Incorporation or Bylaws
7:30am
8-K
cz4r0axwl
25 Apr 23
Other Events
5:10pm
8-K
lje d6vlfm8b8
11 Apr 23
Other Events
12:05pm
8-K
b7gts08ayupbma 97d
9 Mar 23
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
7:36am
8-K
bjz0dwa8 w2qak5xs
2 Mar 23
Entry into a Material Definitive Agreement
4:06pm
8-K
rgwwjo4t2riwa3 tnk88
21 Feb 23
Akebia Therapeutics Received Interim Response from the FDA to Appeal for Vadadustat
6:52am
8-K
ocrg82qegpsw tgb
9 Jan 23
Regulation FD Disclosure
8:31am
8-K
0ea4ih77
28 Dec 22
Entry into a Material Definitive Agreement
8:15am